Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Obesity and Therapeutics
casinoplus vdcasino betriyal betriyal betriyal betriyal betriyal betriyal betriyal betriyal betriyal casinoplus casinoplus casinoplus maltcasino almanbahis melbet betsat fenomenbet betmatik
Govind Kulkarni Author
Subjects of specialization
Affiliation
Clinical & Interventional Cardiology, Stress management
Pulse Diabetes, Obesity & Cardiac Relief Center, India.
Biography
Dr. Govind Kulkarni is M.D in internal medicine from India 1995-96. He completed cardiology research fellowship at sydney university in 1996-97. He is founder of Pulse diabetes obesity and cardiac relief centre Pune India. He is senior consulting physician and metabolic disorder consultant in Major Hospitals Pune, Maharashtra, India.
Publications
Editorial Open Access
Obesity Summit 2018: PCSK9 inhibitors: FOURIER study- Govind Kulkarni- Pulse Diabetes, Obesity & Cardiac Relief Center, India
Author(s): Govind Kulkarni
Background: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers Low-Density Lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods: We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive Evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable... view more»
Google Scholars / Researchers Sites
